Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Lactobacillus rhamnosus K03 (L8020) for peri-implantitis with suppuration
jRCTs061230059Completed
- Sponsor
- Jex
- Start
- Oct 2023
- Modality
- Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of Lactobacillus rhamnosus K03 in peri-implantitis, sponsored by Jex. Primary endpoint: Improvement rate of peri-implantitis (remission of suppuration at 7 days). Started Oct 2023; status: completed.
02
Drugs
Lactobacillus rhamnosus K03
03
Conditions
peri-implantitis
Beyond the preview
Go deeper on jRCTs061230059.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061230059.